Pharmaceutical Law & Industry Report® Index-Summary

TARCERA

– Cancer drug patent infringement suit dismissed in India, 543

TAXATION

– Swap-and-assign transactions were loans (D.N.J.), 1033

TENNESSEE

– Disclosing drug cost information, bill passed, 621
– TennCare dual eligibles reimbursed at 100 percent of Medicare charge, bill signed, 865

TEXAS

– Medicaid

– – Immune system drug maker settles overcharge claims (Tex. Dist. Ct.), 969

– Medicaid, false claims complaint against Risperdal makers amended (Tex. Dist. Ct.), 14

TOPAMAX

– Anticonvulsant, generic exclusivity awarded by FDA, 469
– Seizure drug, generic, In Brief, 385; approved, In Brief, 415

TRASYLOL

– Bleeding drug product liability suit remanded to state court (S.D. Ill.), 1227

TREANDA

– Lymphoma drug, skin reaction reported, 513

TRICOR

– Anti-cholesterol drug, consumer suit over generic delay, settlement approved (D. Del.), 500

TRILEPTAL

– Epilepsy drug blamed for multi-organ sensitivity, suit dismissed (S.D. Ohio), 970

TROVAN

– Antibiotic clinical trials, maker accused of violating international norms (2nd Cir.), 147; (U.S., rev sought), 854
– Nigerian clinical trial claims

– – Kano settles with Pfizer, 913

– Nigerian settlement, hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 616

TRUVADA

– HIV drug ANDA infringes patent (S.D.N.Y.), 10

TYSABRI

– Disclosures, In Brief, 1149
– MS drug maker breached collaboration pact (S.D.N.Y.), 1029
– Viral infections reported to FDA, 1113

TYVASO

– Hypertension drug approved, 923